65.66
price down icon0.23%   -0.15
pre-market  Pre-market:  66.30   0.64   +0.97%
loading
Cytokinetics Inc stock is traded at $65.66, with a volume of 1.84M. It is down -0.23% in the last 24 hours and down -14.83% over the past month. Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$65.81
Open:
$65.37
24h Volume:
1.84M
Relative Volume:
0.91
Market Cap:
$9.13B
Revenue:
$105.82M
Net Income/Loss:
$-829.61M
P/E Ratio:
-9.5953
EPS:
-6.8429
Net Cash Flow:
$-548.92M
1W Performance:
-6.09%
1M Performance:
-14.83%
6M Performance:
+9.40%
1Y Performance:
+35.97%
1-Day Range:
Value
$64.89
$66.47
1-Week Range:
Value
$64.72
$70.18
52-Week Range:
Value
$47.22
$88.31

Cytokinetics Inc Stock (CYTK) Company Profile

Name
Name
Cytokinetics Inc
Name
Phone
(650) 624-3000
Name
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Employee
673
Name
Twitter
@Cytokinetics
Name
Next Earnings Date
2026-11-04
Name
Latest SEC Filings
Name
CYTK's Discussions on Twitter

Compare CYTK vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CYTK icon
CYTK
Cytokinetics Inc
65.66 9.13B 105.82M -829.61M -548.92M -6.8429
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
522.38 132.40B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
796.02 81.95B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
194.82 77.78B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
962.22 60.20B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
199.86 42.84B 742.00K -1.37B -1.07B -7.0731

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-10-26 Initiated Wells Fargo Overweight
Jan-28-26 Resumed Barclays Overweight
Dec-18-25 Upgrade Goldman Neutral → Buy
Jul-30-25 Resumed Raymond James Mkt Perform
Apr-24-25 Initiated Barclays Overweight
Feb-07-25 Initiated Citigroup Buy
Jan-22-25 Initiated Stifel Buy
Nov-08-24 Initiated RBC Capital Mkts Outperform
Aug-13-24 Downgrade Goldman Buy → Neutral
Jan-24-24 Downgrade UBS Buy → Neutral
Jan-05-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-23 Initiated Goldman Buy
Nov-07-23 Initiated B. Riley Securities Buy
Aug-15-23 Initiated SVB Securities Outperform
Feb-17-23 Initiated BofA Securities Neutral
Dec-23-22 Reiterated Needham Buy
Dec-20-22 Initiated Truist Buy
Oct-11-22 Initiated UBS Buy
Jan-28-22 Initiated Goldman Buy
Dec-22-21 Initiated Oppenheimer Outperform
Dec-10-21 Initiated JP Morgan Overweight
Oct-07-21 Initiated Jefferies Buy
Mar-12-21 Initiated Wolfe Research Outperform
Feb-18-21 Initiated Barclays Overweight
Jan-20-21 Reiterated H.C. Wainwright Buy
Oct-29-20 Initiated Goldman Neutral
Jul-10-20 Initiated Raymond James Strong Buy
May-05-20 Initiated Mizuho Buy
Apr-09-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Sep-10-18 Resumed Morgan Stanley Equal-Weight
Nov-22-17 Reiterated Morgan Stanley Overweight
Nov-22-17 Downgrade Needham Strong Buy → Buy
Nov-21-17 Reiterated H.C. Wainwright Buy
Jul-31-17 Initiated Morgan Stanley Overweight
Mar-08-17 Initiated Rodman & Renshaw Buy
Feb-06-17 Upgrade Needham Buy → Strong Buy
Dec-16-16 Initiated Cantor Fitzgerald Overweight
Jul-28-16 Reiterated Needham Buy
Nov-10-15 Reiterated FBR Capital Outperform
Nov-09-15 Reiterated ROTH Capital Buy
Jul-24-15 Reiterated MLV & Co Buy
Dec-31-14 Reiterated ROTH Capital Buy
Nov-04-14 Upgrade MLV & Co Hold → Buy
Apr-28-14 Reiterated Needham Buy
View All

Cytokinetics Inc Stock (CYTK) Latest News

pulisher
04:58 AM

Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance Singapore

04:58 AM
pulisher
Sep 24, 2026

Cytokinetics, Incorporated (CYTK) Stock Forecasts - ca.finance.yahoo.com

Sep 24, 2026
pulisher
Sep 24, 2026

Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance Singapore

Sep 24, 2026
pulisher
Sep 23, 2026

Cytokinetics at bernstein healthcare forum: push beyond first launch By Investing.com - Investing.com South Africa

Sep 23, 2026
pulisher
Sep 23, 2026

Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 23, 2026
pulisher
Sep 23, 2026

Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story? - finance.yahoo.com

Sep 23, 2026
pulisher
Sep 22, 2026

Cytokinetics Inc (CYTK) EVP Research & Development Fady Malik Se - GuruFocus

Sep 22, 2026
pulisher
Sep 22, 2026

Form 4 Cytokinetics Inc For: 22 September - Investing.com India

Sep 22, 2026
pulisher
Sep 22, 2026

Form 4 Cytokinetics Inc For: 22 September By Investing.com - Investing.com Canada

Sep 22, 2026
pulisher
Sep 22, 2026

Cytokinetics EVP Fady Malik sells $239k in company stock - Investing.com

Sep 22, 2026
pulisher
Sep 22, 2026

Cytokinetics EVP Fady Malik sells $239k in company stock By Investing.com - Investing.com Nigeria

Sep 22, 2026
pulisher
Sep 22, 2026

Cytokinetics (CYTK) Insider Trading Activity 2026 $CYTK - MarketBeat

Sep 22, 2026
pulisher
Sep 21, 2026

Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years - Benzinga

Sep 21, 2026
pulisher
Sep 20, 2026

Cytokinetics stock steadies after recent data and guidance updates - AD HOC NEWS

Sep 20, 2026
pulisher
Sep 19, 2026

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Sep 19, 2026
pulisher
Sep 17, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - finance.yahoo.com

Sep 17, 2026
pulisher
Sep 17, 2026

Cytokinetics CEO, President & Director Robert Blum Sells 44% Of Holding - simplywall.st

Sep 17, 2026
pulisher
Sep 16, 2026

Cytokinetics CEO Blum’s trust sells $6.7m in company shares By Investing.com - za.investing.com

Sep 16, 2026
pulisher
Sep 16, 2026

Cytokinetics director Robert Landry sells $72,130 in shares - Investing.com

Sep 16, 2026
pulisher
Sep 16, 2026

Cytokinetics CEO Blum’s trust sells $6.7m in company shares - Investing.com

Sep 16, 2026
pulisher
Sep 15, 2026

Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Shares - GuruFocus

Sep 15, 2026
pulisher
Sep 15, 2026

Trust tied to Cytokinetics (NASDAQ: CYTK) CEO moves to sell shares - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

Family trust tied to Cytokinetics (NASDAQ: CYTK) CEO just sold about 98,000 shares - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

Cytokinetics CEO Robert I. Blum Discloses Stock Option Exercises, Sales, and Trust Transfers - Kalkine Media

Sep 15, 2026
pulisher
Sep 14, 2026

Cytokinetics at Morgan Stanley conference: launch gains and broader bets - Investing.com

Sep 14, 2026
pulisher
Sep 14, 2026

Patient advocacy groups have until Oct. 2 to apply for heart disease outreach grants - Stock Titan

Sep 14, 2026
pulisher
Sep 14, 2026

Landry Robert E Disposes of 1,000 CYTOKINETICS INC Shares at $74.66 on September 11, 2026 - Kalkine Media

Sep 14, 2026
pulisher
Sep 11, 2026

Cytokinetics director Robert Landry sells $74,660 in shares By Investing.com - Investing.com South Africa

Sep 11, 2026
pulisher
Sep 11, 2026

Cytokinetics director Robert Landry sells $74,660 in shares - Investing.com

Sep 11, 2026
pulisher
Sep 11, 2026

Cytokinetics (NASDAQ: CYTK) director plans 2,000-share Rule 144 sale - Stock Titan

Sep 11, 2026
pulisher
Sep 11, 2026

If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga

Sep 11, 2026
pulisher
Sep 11, 2026

Cantor Fitzgerald reiterates Overweight on Cytokinetics stock By Investing.com - Investing.com Australia

Sep 11, 2026
pulisher
Sep 11, 2026

Cantor Fitzgerald reiterates Overweight on Cytokinetics stock - Investing.com

Sep 11, 2026
pulisher
Sep 10, 2026

Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says - marketscreener.com

Sep 10, 2026
pulisher
Sep 09, 2026

Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com Nigeria

Sep 09, 2026
pulisher
Sep 09, 2026

Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03 - marketscreener.com

Sep 09, 2026
pulisher
Sep 09, 2026

Cytokinetics at citigroup summit: hcm expansion drives growth hopes - Investing.com

Sep 09, 2026
pulisher
Sep 08, 2026

Cytokinetics (CYTK) Insider Sell: EVP Research & Development Fad - GuruFocus

Sep 08, 2026
pulisher
Sep 07, 2026

Could Aficamten Give Cytokinetics the First Approved nHCM Treatment? - Yahoo Finance

Sep 07, 2026
pulisher
Sep 07, 2026

Cytokinetics, Inc. (CYTK) Stock Analysis: Biotech Growth With 51% Upside Potential - DirectorsTalk Interviews

Sep 07, 2026
pulisher
Sep 04, 2026

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - Zacks Investment Research

Sep 04, 2026
pulisher
Sep 02, 2026

Cytokinetics to Participate in September Investor Conferences - marketscreener.com

Sep 02, 2026
pulisher
Sep 02, 2026

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects? - Eastern Progress

Sep 02, 2026
pulisher
Sep 01, 2026

Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus

Sep 01, 2026
pulisher
Sep 01, 2026

Cytokinetics Insider Sold Shares Worth $357,400, According to a Recent SEC Filing - marketscreener.com

Sep 01, 2026
pulisher
Sep 01, 2026

Cytokinetics (NASDAQ: CYTK) director sale under 10b5-1 plan - Stock Titan

Sep 01, 2026
pulisher
Sep 01, 2026

Cytokinetics (NASDAQ: CYTK) director moves to sell 5,000 vested shares - Stock Titan

Sep 01, 2026
pulisher
Sep 01, 2026

Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $112 - Moomoo

Sep 01, 2026
pulisher
Sep 01, 2026

Cytokinetics (CYTK) Presents New Phase 3 Data, Is It Still 34% Undervalued? - Yahoo Finance

Sep 01, 2026
pulisher
Sep 01, 2026

Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential - Investing.com

Sep 01, 2026
pulisher
Sep 01, 2026

Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential By Investing.com - Investing.com Canada

Sep 01, 2026

Cytokinetics Inc Stock (CYTK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$58.29
price up icon 1.11%
$36.13
price down icon 1.87%
$121.55
price up icon 2.71%
$249.59
price up icon 1.25%
ONC ONC
$359.97
price down icon 1.38%
$199.86
price up icon 4.78%
Cap:     |  Volume (24h):